Biotechnology involves the application of biological systems and organisms to develop medicinal products, particularly biologics such as monoclonal antibodies, proteins, and gene and cell therapies. Biologics differ fundamentally from small-molecule medicines in terms of their complexity, manufacturing methods, and regulatory requirements. Their development requires specialized expertise in cell culture, protein purification, analytical characterization, and immunogenicity assessment.
For studies involving biologics, CROs must develop specific capabilities: temperature-controlled supply chains for sensitive products, specialized storage facilities, and trained personnel for complex handling procedures. Immunogenicity assessment is a critical aspect that requires specialized assay development and regulatory expertise. The development of biosimilars presents additional challenges and requires extensive comparability studies.
Emerging areas such as gene therapies, cell therapies, and mRNA-based therapeutics require highly specialized infrastructure and regulatory expertise. CROs therefore invest in GMP manufacturing capacity and specialized laboratories to meet these requirements.